The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy

Yonsei University207 enrolled

Overview

To evaluate the efficacy of usual monotherapy and low dose combination of Lamotrigine and Valproate. Low dose combination may be more effective and tolerable because they are low dose and VPA reduce Lamotrigine metabolism.

An Open label, Randomized, Multicenter Clinical Trial to Compare the Efficacy and Safety of Lamotrigine / Valproate Coadministration and Carbamazepine as Initial Pharmacotherapy in Epilepsies

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

207

Conditions

Epilepsy

Interventions

CarbamazepineDRUG

Lamotrigine/ValproateDRUG

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥16yr old * Who are diagnosed as epilepsy definitely * Who have minimum 2 unprovoked seizures and minimum 1 seizure in previous 3 months * Who need AED therapy and no AED medication for previous 1 year (exclude emergency medication for less than 2weeks) * Who is not pregnant * Who can report seizure diary by him/herself or caregiver * Who agree to this trial and provide informed consent. * Type of seizures : of generalized tonic-clonic, complex partial, and/or simple partial motor seizures; Exclusion Criteria: * Who has progressive CNS disease. * Has serious systemic or psychiatric disease * Who is not suitable by investigator(uncooperative) * Who can not fill up diary check card * Is pregnant, breastfeeding, or planning to become pregnant * Exclusion - absence s. juvenile myoclonic epilepsy, atonic seizure, alcohol or other substance abusers, mental retardation etc. * Who cancels to agree to this trial and provide informed consent. * ALT, AST, bilirubin and BUN/Cr levels are more than twice normal range of them * WBC value is 2000 and less, Hb value is 9.0 and less, platelet count is 100,000 and less in CBC * Who took investigation products before participating this study

Locations (1)

Yonsei Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

Retention Rate After 52 Weeks Maintenance Period

\* Retention rate means completion rate (CR), the proportion of patients who have completed the 60-week study as planned.

Time frame: 52 weeks

Secondary Outcomes

Seizure Free Rate for 24 Weeks at Initial Target Dose

Time frame: 24 weeks

Seizure Free Rate for 52 Weeks at Initial Target Dose

Time frame: 52 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.